# Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

> **NCT00842998** · PHASE2 · UNKNOWN · sponsor: **Azienda Ospedaliera Ordine Mauriziano di Torino** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Trastuzumab or Lapatinib

## Key facts

- **NCT ID:** NCT00842998
- **Lead sponsor:** Azienda Ospedaliera Ordine Mauriziano di Torino
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-02
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2009-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00842998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00842998, "Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00842998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*